Polysaccharides Patents (Class 536/55.1)
  • Patent number: 10973858
    Abstract: A nerve growth promoter and an antioxidant containing a degradation product obtained by degrading a composition containing a hyaluronic acid and a protein with a protease. A would treatment agent containing an ethyl acetate extract of a degradation product obtained by degrading a composition containing a hyaluronic acid and a protein with a protease.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 13, 2021
    Assignee: LAIMU CORPORATION
    Inventors: Sachio Wakayama, Akihiro Tai
  • Patent number: 10787693
    Abstract: Single-chain ?-glucans can be obtained by hydrothermal treatment of a solution containing (1,3)(1,6)-?-glucan for a predetermined time in a temperature range of from 145° C. to 200° C. at a pressure at or above the saturated vapor pressure at the treatment temperature. ?-Glucans capable of maintaining a single-chain state for an extended period of time can be produced without chemical treatment.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 29, 2020
    Assignee: ITOCHU SUGAR CO., LTD.
    Inventors: Nobuhiro Kondo, Katsuki Hirabayashi
  • Patent number: 10647738
    Abstract: The present invention relates to a xylene-based amphiphilic compound, a method for preparing the same, and a method for extracting, solubilizing, stabilizing or crystallizing a membrane protein using the same. By using the xylene-based compound according to the present invention, a membrane protein may be stably stored in an aqueous solution for a long time, and may be applied in functional and structural analyses. The structural and functional analysis of the membrane protein is one of the fields of highest interest in biology and chemistry, and the xylene-based compound according to the present invention can be applied in research on protein structure that is closely related to development of a new drug.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 12, 2020
    Assignee: Industry-University Cooperation Foundation
    Inventors: Pil Seok Chae, Kyung Ho Cho
  • Patent number: 10435523
    Abstract: The present disclosure provides, inter alia, a method of producing an outer layer material for forming into a structure and that comprises an entanglement having a hydrophobic polymer host and a hydrophilic guest, including in one embodiment the steps of: intermingling cloaked hydrophilic guest complexes with the hydrophobic host; crosslinking molecules of the guest with the guest; and performing a hydrolysis reaction.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 8, 2019
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Susan P. James, Min Zhang, Guy Beauregard, Rachael Kurkowski Oldinski
  • Patent number: 10336784
    Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: July 2, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Sachin S. Shivatare
  • Patent number: 10328097
    Abstract: Glycosaminoglycan esters, wherein at least part of the hydroxyl groups present on the N-acetylglucosamine residue are esterified with an apocarotenoid, their preparation, and their use in formulations for ophthalmic use are described.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: June 25, 2019
    Assignee: Hyalblue S.R.L.
    Inventors: Nikla Baricordi, Roberto Merighi
  • Patent number: 9820995
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: November 21, 2017
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Patent number: 9597277
    Abstract: The present invention relates to the use of a thiol-group-containing polymer for preparing an implant for tissue augmentation, wherein the basis polymer is a polysaccharide.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: March 21, 2017
    Assignee: CROMA-PHARMA GESELLSCHAFT M.B.H.
    Inventor: Margit Hornof
  • Patent number: 9468653
    Abstract: The present invention relates to the a bismuth-based composition, particularly involving the use of bismuth ions, particularly the Bi+3 ion, for prevention and/or treatment of the haemolytic uremic syndrome, with the invention also relating to the use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of an infection caused by a Shiga-toxin producing Escherichia coli strain, as well as to a method for preventing and/or treating the haemolytic uremic syndrome comprising administering bismuth ions to a patient in need thereof, and a method for inhibiting dissemination of the gene encoding virulence factors of a Shiga-toxin producing Escherichia coli strain in animals and humans.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: October 18, 2016
    Assignee: Soubeiran Chobet
    Inventor: Hector Manuel Fernandez
  • Patent number: 9446067
    Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: September 20, 2016
    Assignee: Bioregen Biomedical (Changzhou) Co. Ltd.
    Inventors: Xiaozheng Shu, Weiping Zhong, Yunyun Wang, Meixia Yu
  • Patent number: 9394378
    Abstract: Disclosed is a process for the production of chondroitin sulphate, wherein N-acetyl-galactosamine residues sulphated at the 4- or 6-positions are present on the same polysaccharide chain.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: July 19, 2016
    Assignee: ALTERGON S.A.
    Inventors: Emiliano Bedini, Mario De Rosa, Cristina De Castro, Annalida Di Nola, Michelangelo Parrilli, Odile Francesca Restaino, Chiara Schiraldi
  • Patent number: 9220632
    Abstract: Methods of treating ocular disorders are disclosed, including: inserting an implant in eye tissue, using an instrument, such that an inlet portion of the implant is in an anterior chamber of an eye and an outlet portion of the implant is in a physiological outflow pathway; removing the instrument from the eye without removing the implant; and conducting fluid comprising a therapeutic substance through the implant and into the physiological outflow pathway. Another method includes inserting an instrument into a physiologic outflow pathway through which aqueous humor drains from an anterior chamber of an eye; separating first and second walls of tissues which comprise the physiologic outflow pathway by injecting a fluid comprising a drug from the instrument while the instrument remains in the physiologic outflow pathway; and withdrawing the instrument with said fluid remaining within the eye such that the drug has a therapeutic effect on the eye.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 29, 2015
    Assignee: GLAUKOS CORPORATION
    Inventors: Gregory Smedley, David Haffner, Hosheng Tu
  • Patent number: 9090644
    Abstract: Processes for the synthesis of lipochitooligosaccharides were developed. A fully acylated oligoglucosamine precursor is prepared and reacted with a glucosamine monomer that has an amine protecting phthaloyl group. With removal of the phthaloyl group, a fatty acid may be added on the terminal glucosamine unit, forming a lipochitooligosaccharide. The processes can be adapted for use on a commercial scale.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: July 28, 2015
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventor: Subramaniam Sabesan
  • Publication number: 20150147379
    Abstract: The embodiments relate generally to medical devices and to methods of their manufacture. One aspect provides devices including chitosan fibers that are a free of chemical cross linking. Another aspect provides a method of manufacturing such devices.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 28, 2015
    Applicant: COOK MEDICAL TECHNOLOGIES LLC
    Inventor: Mohammad Z. Albanna
  • Publication number: 20150119356
    Abstract: The invention relates to an ophthalmic viscoelastic device, comprising at least one viscoelastic polymer, wherein the at least one viscoelastic polymer is covalently bound to at least one phenolic compound. The invention also relates to a method for producing an ophthalmic viscoelastic device, in which at least one phenolic compound is covalently bound to at least one water-soluble, viscoelastic polymer.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 30, 2015
    Applicant: Carl Zeiss Meditec AG
    Inventors: Andre Wolfstein, Gillian Rodden, Jurgen Nachbaur, Claude De Moissonnier, Pascal Bernard, Gildas Lorec, Nicole Bielefeldt, Brian Rathert, Lidia Nachbaur, Mario Gerlach, Alistair Rennie
  • Patent number: 9018372
    Abstract: The invention relates to a bonding product comprising at least the polysaccharides T1 and T2, characterized in that a) the monosaccharides from which the polysaccharides T1 and T2 are constructed are partially or completely bonded to each other alpha-1,4-glycosidically and b) at least one of the polysaccharides T1 and/or T2 comprises at least one amino group and c) T1 and T2 are chemically bonded to each other covalently by at least one linker Z and d) T1 and/or T2 carries m groups -(L-A), wherein A is an active pharmaceutical ingredient and/or a fluorescence label, L is a second linker, by which T1 and/or T2 is covalently bonded to A, and m is an integer, which is 0 or at least 1.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: April 28, 2015
    Assignee: B. Braun Melsungen AG
    Inventors: Bernd Horst Meier, Iris Jankowiak-Meier, Nele Meier, Clara Meier
  • Patent number: 9012413
    Abstract: The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3? or hydroxyl group, R3 is an alkyl, cycloalkyl, or alkyl-cycloalkyl group, R4 is a disaccharide having Formula (II), R6 is a disaccharide having Formula (III), and R8 is a disaccharide having Formula (IV), where R5, R7, and R9 are OSO3? or hydroxyl groups. The invention further relates to the preparation of said octasaccharides and to the therapeutic use thereof.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: April 21, 2015
    Assignee: Sanofi
    Inventors: Pierre Alexandre Driguez, Philippe Duchaussoy, Pierre Fons, Corentin Herbert, Gilbert Lassalle
  • Publication number: 20150087821
    Abstract: The present invention provides a new method for isolation and/or purification of immunoglobulins from a solution containing one or more immunoglobulins using a solid phase matrix represented by the formula: M-SP-L, wherein M is designates a matrix backbone, SP designates a spacer and L designates a substituted benzimidazole ligand.
    Type: Application
    Filed: December 5, 2014
    Publication date: March 26, 2015
    Inventors: Gordon R. Duffin, Victoria Jane Dolan, Katherine Louise Angus, Andrew Lyddiatt
  • Patent number: 8987230
    Abstract: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: March 24, 2015
    Assignees: National University Corporation Tokyo Medical and Dental University, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kazunari Akiyoshi, Nobuyuki Morimoto, Tai Hirakura, Tsuyoshi Shimoboji
  • Publication number: 20150076046
    Abstract: An anion adsorbent of an embodiment includes a support and a triazine hydrochloride structure that is bound to the support.
    Type: Application
    Filed: August 26, 2014
    Publication date: March 19, 2015
    Applicant: Kabushiki Kaisha Toshiba
    Inventors: Yumiko SEKIGUCHI, Tomohito IDE, Hideyuki TSUJI
  • Patent number: 8951990
    Abstract: Described herein are methods for treating a dental disorder in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C1-C10 unsubstituted alkyl group or fluoroalkyl group.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: February 10, 2015
    Assignee: University of Utah Research Foundation
    Inventors: Glenn Prestwich, Jianxing Zhang, Sr., Thomas P. Kennedy, Narayanam Rao
  • Patent number: 8946406
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: February 3, 2015
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20150030626
    Abstract: The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.
    Type: Application
    Filed: November 9, 2012
    Publication date: January 29, 2015
    Applicant: Ascend Biopharamaceuticals Ltd
    Inventors: Geoffrey Alan Pietersz, Clement Leong
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20150018522
    Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 15, 2015
    Applicant: The United States of America, as represented by the Secretary, Department of Health & Human Servic
    Inventors: Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
  • Patent number: 8933054
    Abstract: A low-molecular-weight hyaluronic acid and/or its salt is obtained by dispersing hyaluronic acid and/or its salt in an acidic water-containing medium.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: January 13, 2015
    Assignee: Q.P. Corporation
    Inventor: Takushi Yoshida
  • Publication number: 20150005485
    Abstract: Preparation and use of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides useful for the preparation of synthetic heparinoids.
    Type: Application
    Filed: January 29, 2014
    Publication date: January 1, 2015
    Applicant: ALCHEMIA LIMITED
    Inventors: Joachim SEIFERT, Latika SINGH, Tracie E. RAMSDALE, Michael L. WEST, Nicholas B. DRINNAN
  • Publication number: 20140378532
    Abstract: The present invention relates to glycogen-based cationic polymers, to complexes of the said cationic polymers with anionic compounds, to pharmaceutical compositions comprising the said complexes, and to the use of the said complexes for delivering or transfecting the said anionic compounds to a specific pharmacological target, such as, for instance an organ, a tissue or a cell.
    Type: Application
    Filed: February 21, 2013
    Publication date: December 25, 2014
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla
  • Publication number: 20140336369
    Abstract: Processes are disclosed for the synthesis of the Factor Xa anticoagulant fondaparinux and related compounds. Protected pentasaccharide intermediates and efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions are provided.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Applicant: APICORE US LLC
    Inventors: Ravishanker Kovi, Ashish Naik, Brijesh Patel, Muralikrishna Madala
  • Patent number: 8871923
    Abstract: The present invention generally relates to new plant elicitor compositions, and the use of these compositions in agricultural applications, more particularly to protect plants against (infection by) plant pathogens and the corresponding methods of, and uses in, the protection of plants and crops by application of these compositions.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: October 28, 2014
    Assignee: FYTOFEND S.A.
    Inventors: Raffaele Buonatesta, Géraldine Van Aubel, Pierre Van Cutsem
  • Patent number: 8871744
    Abstract: The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: B & G Partyers, LLC
    Inventor: Donald L. Barbeau
  • Publication number: 20140314804
    Abstract: The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. In another aspect, compositions that generally include an antigen component, a soluble beta-glucan component, and a TLR agonist component and a method that generally includes administering to a subject a composition that comprises a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen, are described.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 23, 2014
    Inventors: Keith B. Gorden, Nandita Bose, Anissa S.H. Chan, William J. Grossman
  • Patent number: 8846899
    Abstract: Disclosed are saccharide and phosphocholine derivatives. The derivatives include azide and alkyne derivatives which form one end of a variable length carbon chain. The opposite end of the variable length carbon chain is covalently linked to the saccharide or phosphocholine. The saccharide may be, for instance, a maltoside. The alkyne and azide derivatives of the saccharides and phosphocholine may be reacted together to form amphiphilic molecules useful in cellular membrane studies and applications. By adjusting the length of the carbon chain, the biochemical and biophysical properties of the resultant 1,4-disubstituted 1,2,3-triazole compounds may be custom tailored for the intended application. Resultant molecules may form micelles, bicelle, lipid bilayers and other like structures useful in the isolation and purification of membrane bound or membrane associated proteins and biochemical components.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: September 30, 2014
    Assignee: Anatrace Products, LLC
    Inventors: Benjamin R. Travis, Ritesh Mittal, Lijun Huang, Liang Tang
  • Patent number: 8841440
    Abstract: Organo-soluble chitosan salts, method for preparing organo-soluble salts, chitosan-derived materials prepared with organo-soluble chitosan salts, and methods for preparing chitosan-derived materials are disclosed.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: September 23, 2014
    Assignee: Cornell University
    Inventors: Chih-Chang Chu, Chao Zhong
  • Publication number: 20140273049
    Abstract: A diagnostic marker for digestive organ cancer according to the present invention is used for determining whether or not to have a digestive organ cancer. The diagnostic marker for digestive organ cancer contains at least one of N-binding type sugar chains released from a glycoprotein contained in blood and represented by the following formulas (1) to (6). This makes it possible to provide a diagnostic marker for digestive organ cancer capable of being used for an inspection method of easily determining whether or not to have a digestive organ cancer at an early stage, and an inspection method for digestive organ cancer of easily determining whether or not to have a digestive organ cancer at an early stage.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 18, 2014
    Applicants: Kagoshima University, SUMITOMO BAKELITE COMPANY LIMITED
    Inventors: Shoji Natsugoe, Yasuto Uchikado, Teruto Hashiguchi, Hiroyuki Shinchi, Kosei Maemura, Yuko Mataki, Norichika Moriwaki, Masaru Sekijima, Hideyuki Shimaoka, Midori Sakaguchi, Masao Fukushima, Kota Igarashi, Hiroki Abe, Taichi Aihara
  • Patent number: 8828968
    Abstract: A nanoparticle of glucidamin derived from organism for treating tumor and preparation method thereof, wherein the viscosity-average molecular weight of glucidamin is in the range of 1×103-9×105, and the amount of free amino groups in the glucidamin is in the range of 50%-100% based on the total amino groups. The preparation method of the nanoparticle comprises steps listed below: (1) adding the glucidamin possessing one or more molecular weight into thin acid solution at 20-60° C. to form saccharan solution, wherein the content of saccharan in solution is in the range of 0.1%-5% by weight; (2) adjusting the pH of the solution to 6-9 in order to form emulsion of microparticle; (3) separating the microparticle from the emulsion, dried at low temperature to obtain the nanoparticle of glucidamin for treating tumor. The nano-class glucidamin can enhance their activity against tumor.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: September 9, 2014
    Assignee: Ningbo Puai Bioengineering Co., Ltd.
    Inventor: Zirong Xu
  • Patent number: 8829181
    Abstract: The present invention relates to a process for producing a cationic hydroxypropyl cellulose including the step of reacting a low-crystalline powdery cellulose with a cationizing agent represented by the following general formula (1) and/or a cationizing agent represented by the following general formula (2), and propylene oxide in the presence of water in an amount of from 10 to 60% by mass on the basis of the low-crystalline powdery cellulose, and a catalyst: wherein R1 to R3 are each independently a linear or branched hydrocarbon group having 1 to 4 carbon atoms; and X and Z are each a halogen atom and may be the same or different from each other.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: September 9, 2014
    Assignee: KAO Corporation
    Inventors: Masanori Takai, Masafumi Miyamoto, Kohei Nakanishi, Toru Nishioka
  • Patent number: 8822433
    Abstract: The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): RxSi(OH)4-x, (I) wherein: R is a (C1-C4)alkyl, and x=1 or 2. The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: September 2, 2014
    Assignee: Exsymol S.A.M.
    Inventor: Marie-Christine Seguin
  • Patent number: 8809300
    Abstract: Disclosed is a depolymerized glycosaminoglycan from Thelenota ananas (dTHG), weight average molecular weight of which is about 8000˜20000 Da, and monosaccharide components of which are acetylgalactosamine (GalNAc), glucuronic acid (GlcUA), fucose (Fuc) or their sulfates (expressed as —OSO3?), in which molar ratio of GalNAc:GlcUA:Fuc:—OSO3? is about 1:(1±0.3):(1±0.3):(3.5±0.5). Said dTHG is a potent endogenous inhibitor of factor X, which has good anticoagulant and antithrombotic activity, and can be used for the prevention and/or treatment of thrombotic diseases. Also provided is a method for preparing said dTHG, which comprises steps of 1) extracting and obtaining fucosylated glycosaminoglycan (THG) from the body wall of Thelenota ananas; 2) depolymerizing THG to obtain dTHG by method of peroxide depolymerization or method of peroxide depolymerization catalyzed by catalyst of the fourth period transition metal ions; 3) removing impurities with lower and/or higher molecular weight in dTHG.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: August 19, 2014
    Assignee: Shenzhen Neptunus Pharmaceutical Co., Ltd.
    Inventors: Jinhua Zhao, Hui Kang, Mingyi Wu, Weizhen Zeng, Zi Li, Yuan Gao, Jing Cui, Zhiguo Wang, Hanlin Feng, Lin Yu
  • Patent number: 8802841
    Abstract: A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: August 12, 2014
    Assignee: Glycom A/S
    Inventors: Gyula Dekany, István Bajza, Marie Bøjstrup, Károly Ágoston, Lars Kröger, Ignacio Figueroa Pérez, Christoph H. Röhrig, Paulo Vital, Erzsébet Czinege
  • Publication number: 20140220046
    Abstract: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
    Type: Application
    Filed: January 15, 2014
    Publication date: August 7, 2014
    Applicant: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
  • Publication number: 20140219917
    Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 7, 2014
    Applicants: Emory University, Georgia State Research Foundation, Georgia Tech Research Corporation
    Inventors: Niren MURTHY, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
  • Publication number: 20140187499
    Abstract: The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic acids, N-acetylhexosamines in cyclic form or in open reduced form, which are randomly substituted. It also relates to the process for the preparation thereof and to the pharmaceutical compositions comprising same.
    Type: Application
    Filed: November 13, 2013
    Publication date: July 3, 2014
    Inventors: Gérard SOULA, Emmanuel DAUTY, Richard CHARVET
  • Publication number: 20140179911
    Abstract: The present invention relates to plant cells and plants which synthesize hyaluronan and to methods for preparing such plants, and also to methods for preparing hyaluronan with the aid of these plant cells or plants. Furthermore, the present invention relates to the use of plants for preparing hyaluronan and to food or feed which comprises hyaluronan.
    Type: Application
    Filed: September 23, 2013
    Publication date: June 26, 2014
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Claus FROHBERG, Rainhard KOCH
  • Patent number: 8759322
    Abstract: The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): wherein R1, R2, R3, R4, Z, n, Ra, Y, and X1 are as defined in the specification.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: June 24, 2014
    Assignees: National University Corporation Tokyo Medical and Dental University, Chugau Seiyaku Kabushiki Kaisha
    Inventors: Kazunari Akiyoshi, Takashi Nakai, Tai Hirakura, Tsuyoshi Shimoboji
  • Publication number: 20140170151
    Abstract: The present invention synthetic oligo-?-(1?6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-?-(1?6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-?-(1?6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-?-(1?6)-glucosamines, such as Staphylococcus aureus.
    Type: Application
    Filed: February 11, 2014
    Publication date: June 19, 2014
    Inventors: A. Stewart CAMPBELL, Obadiah J. PLANTE
  • Patent number: 8748409
    Abstract: Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C1-10 hydrocarbon group, Y is a polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R2, with R2 being a C1-23 hydrocarbon group. The hydrogel has excellent viscoelasticity and can be injected into a predetermined location with an injection device such as a syringe, and thus can be advantageously used as a medical gel or an adhesion barrier.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: June 10, 2014
    Assignee: Teijin Limited
    Inventors: Hiroaki Kaneko, Masaya Ito
  • Publication number: 20140147479
    Abstract: Particles according to the invention are made of a viscoelastic medium, are injectable gel particles, and have a size, when subjected to a physiological salt solution, in the range of from 1 to 5 mm. The particles are useful in a soft tissue augmentation implant. The implant comprises particles of a viscoelastic medium, wherein a major volume of the particles are injectable gel particles according to the invention. The implant is useful in a method of soft tissue augmentation in a mammal, including man, comprising subepidermal administration at a site in said mammal where soft tissue augmentation is desirable, of an implant according to the invention.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: Q-Med AB
    Inventor: Bengt AGERUP
  • Patent number: 8728486
    Abstract: The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: May 20, 2014
    Assignee: University of Kansas
    Inventors: Sunil A. David, Nikunj M. Shukla
  • Patent number: 8703293
    Abstract: Provided herein re a composition and a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: April 22, 2014
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Lothar W. Kleiner, Connie S. Kwok